GLP-1 Microdosing and HIV: Weight Gain on Modern Antiretrovirals, Belly Fat, and What the Semaglutide Studies Show
GLP-1 microdosing in people with HIV has never been tested in a trial, but GLP-1 medicines at standard doses have. Semaglutide studies in people with controlled HIV report a large drop in deep belly fat, signs of improving fatty liver, some muscle loss without a loss of function, and a clear rebound once the drug stops.
8.9 kg
MEAN WEIGHT GAIN OVER 192 WEEKS ON TAF/FTC + DOLUTEGRAVIR IN THE ADVANCE TRIAL
30.6%
DROP IN VISCERAL BELLY FAT ON SEMAGLUTIDE IN PEOPLE WITH HIV LIPOHYPERTROPHY
2.9 kg
MEAN WEIGHT REGAINED IN 24 WEEKS AFTER STOPPING SEMAGLUTIDE 1 MG (SLIM LIVER)
For many people living with HIV, the virus is no longer the daily problem. The viral load has been undetectable for years. What shows up at clinic visits instead is a waistband that keeps tightening, a fasting glucose creeping up, and a scan that mentions fatty liver.
This article looks at why weight gain has become common on modern HIV treatment, what happens when people switch regimens to fix it, and what the semaglutide and liraglutide studies in people with HIV actually found. One limit applies throughout. Every trial here used standard doses, with semaglutide 1 mg weekly as the lowest. Nobody has studied sub-label GLP-1 microdosing in people with HIV, so the numbers below describe tested doses, not microdose protocols.
Key takeaways
- •In the ADVANCE trial, people starting TAF/FTC plus dolutegravir gained a mean 8.9 kg over 192 weeks, against 3.2 kg on an efavirenz-based regimen.
- •In the Do IT randomized trial, switching from an integrase inhibitor to doravirine did not produce clinically meaningful weight differences after 48 weeks.
- •In a placebo-controlled trial of 108 people with HIV-associated lipohypertrophy, semaglutide reduced visceral belly fat by 30.6% over 32 weeks.
- •In SLIM LIVER, semaglutide 1 mg produced a mean 7.8 kg weight loss in 24 weeks, and 2.9 kg returned within 24 weeks of stopping.
- •No trial has tested GLP-1 microdosing in people with HIV; the lowest studied semaglutide dose was 1 mg weekly.
Why do people with HIV gain weight on modern antiretrovirals?
People with HIV gain weight on modern antiretroviral therapy partly because they get healthier and partly because of the drugs themselves. Sax and colleagues, writing in Clinical Infectious Diseases (2020), pooled 8 randomized treatment-start trials run between 2003 and 2015, with more than 5000 participants and 10,000 person-years of follow-up. Integrase inhibitors were linked to more weight gain than protease inhibitors or NNRTIs, with dolutegravir and bictegravir standing out. Tenofovir alafenamide (TAF) was linked to more gain than tenofovir disoproxil fumarate (TDF).
The same analysis found that who you are matters as much as what you take. Lower CD4 counts, higher viral loads, female sex and Black race all predicted more weight gain after starting treatment. The authors concluded the mechanisms behind drug-specific weight gain are still unknown.
The ADVANCE trial in South Africa shows how large the effect can get. Sokhela and colleagues, in Open Forum Infectious Diseases (2024), reported the final 192-week results for 3 first-line regimens.
Mean weight gain over 192 weeks by starting regimen (kg)
Sokhela S et al., ADVANCE trial, Open Forum Infect Dis 2024. Treatment-naive adults in South Africa. DTG = dolutegravir, EFV = efavirenz.
Mean weight gain was 8.9 kg on TAF/FTC plus dolutegravir, 5.9 kg on TDF/FTC plus dolutegravir and 3.2 kg on the efavirenz combination. Gain was greatest among women, people taking TAF and those with lower CD4 counts at the start. The curve did slow after week 96, but it did not reverse.
Does switching HIV medicines take the weight back off?
Switching away from an integrase inhibitor does not reliably reverse the weight gain. Koethe and colleagues tested this directly in the Do IT study (ACTG A5391), published in Clinical Infectious Diseases (2026). They randomized 147 people with HIV and obesity who had been on an integrase inhibitor with TAF/FTC for a median 3.4 years. Median BMI was 34.9, and 49% were women.
Mean weight change after 48 weeks (%)
Koethe JR et al., Do IT study (ACTG A5391), Clin Infect Dis 2026. DOR = doravirine; INSTI = integrase inhibitor.
Weight changed by -0.47% after switching to doravirine with TAF/FTC, -2.73% with TDF/FTC, and -1.84% for those who stayed on their integrase regimen. The authors found no clinically meaningful differences in weight, fasting lipids, insulin resistance, fat mass or bone density. That result is part of why attention has turned to treating the weight itself rather than reshuffling the regimen.
Does semaglutide reduce HIV-associated belly fat?
Semaglutide substantially reduced deep belly fat in the only placebo-controlled GLP-1 trial in HIV-associated lipohypertrophy. Eckard and colleagues, in The Lancet Diabetes & Endocrinology (2024), randomized 108 people with controlled HIV, a BMI of 25 or more and no diabetes to weekly semaglutide or placebo for 32 weeks. The semaglutide arm had an 8-week titration, then 24 weeks at 1.0 mg.
Fat reduction on semaglutide over 32 weeks, by depot (%)
Eckard AR et al., Lancet Diabetes Endocrinol 2024. Randomized, double-blind, placebo-controlled; n=108. Sex-adjusted % change.
Visceral fat, the deep abdominal fat that drives most of the cardiometabolic risk in lipohypertrophy, fell 30.6%. Total body fat fell 18.9% and abdominal fat under the skin fell 11.2%. The bigger drop in visceral fat matters, because lipohypertrophy is defined by fat that collects around the organs rather than just under the skin.
Safety was mostly reassuring but not spotless. There was no statistically significant difference in related adverse events between groups. One semaglutide-related grade 4 lipase elevation and two possibly related cases of gallstones were recorded, and the authors called for larger trials to look for serious adverse events in people with HIV.
What did the SLIM LIVER study find about low-dose semaglutide?
SLIM LIVER (ACTG A5371) found that semaglutide 1 mg weekly, which its investigators call low-dose, improved weight, liver disease and metabolic markers in people with HIV and fatty liver. It is the closest the HIV research comes to a lower-dose protocol. Participants had controlled HIV and metabolic dysfunction-associated steatotic liver disease (MASLD).
Lake and colleagues, in HIV Medicine (2026), analysed blood samples from 36 responders. Twenty-four weeks of low-dose semaglutide improved MASLD severity on serum metabolomic profiling across every severity category. That is an indirect measure rather than a biopsy, but it fits with GLP-1 liver data in people without HIV. Our article on GLP-1 microdosing and fatty liver covers that broader research.
Muscle is the trade-off people worry about. Ditzenberger and colleagues, in Clinical Infectious Diseases (2025), measured it in 46 SLIM LIVER participants. Psoas muscle volume fell 9.3% over 24 weeks. Function did not follow it down.
Participants with slow walking speed, under 1 m/sec (%)
Ditzenberger GL et al., Clin Infect Dis 2025. SLIM LIVER secondary analysis; single-arm, no placebo group.
The share of people with slow gait speed fell from 63% to 46%, and chair-rise times did not worsen. The authors concluded function was maintained despite measurable muscle loss. Because there was no placebo group, this is encouraging rather than conclusive. Resistance training and enough protein remain the sensible companions to any GLP-1 plan, as our guide to muscle preservation on a GLP-1 microdose explains.
What happens after people with HIV stop semaglutide?
After stopping semaglutide, people with HIV regain weight quickly, much as people without HIV do. Erlandson and colleagues, in Clinical Infectious Diseases (2026), followed 49 SLIM LIVER participants through 24 weeks on semaglutide 1 mg and 24 weeks off it. The group had a median age of 52, a median BMI of 35, and 43% were women.
Weight lost on semaglutide 1 mg and regained after stopping (kg)
Erlandson KM et al., Clin Infect Dis 2026. SLIM LIVER (ACTG A5371), n=49. Mean values.
After a mean 7.8 kg loss in the first 24 weeks, participants regained 2.9 kg in the next 24. Waist size rose 2.0 cm and fasting glucose rose 5.1 mg/dL. Blood pressure, cholesterol and triglycerides did not change significantly over that time. The investigators called the pattern rapid regain, similar to the general population.
The lipohypertrophy trial saw the same thing over a longer follow-up. Adekunle and colleagues, in Open Forum Infectious Diseases (2026), followed 80 completers from week 32 to week 56. Weight, waist, total fat and visceral fat rose after semaglutide stopped, and insulin resistance worsened, though weight, BMI and waist size stayed below where people started. The authors concluded that sustained drug exposure is likely needed for long-term benefit. That finding is the core argument for lower-dose maintenance, and also the reason it needs testing. Our article on when the hunger comes back looks at rebound in more detail.
How well do GLP-1 medicines work in everyday HIV care?
Outside trials, GLP-1 medicines still produce weight loss in people with HIV, though smaller amounts. Nguyen and colleagues, in Clinical Infectious Diseases (2024), reviewed 225 patients at a San Diego HIV clinic who took a GLP-1 medicine for an average of 13 months. Mean weight loss was 5.4 kg, BMI fell 1.8 and A1C fell 0.6%. Only 85 people (37.8%) ever reached the maximum dose.
Factors linked to losing more than 5% of body weight (odds ratio)
Nguyen Q et al., Clin Infect Dis 2024. Retrospective single-clinic cohort, n=225. An odds ratio above 1 means higher odds.
Tirzepatide users had an odds ratio of 5.46 for losing more than 5% of body weight, treatment beyond 6 months had 3.12, and each unit of higher starting BMI added a little (1.10). Because this was a retrospective study, people were not randomized to drugs, so these are associations, not head-to-head results.
A short trial in rural South Africa gives a different setting. Behuhuma and colleagues, in Clinical Infectious Diseases (2026), gave 40 people with HIV and a BMI of 30 or more liraglutide 3.0 mg daily for 12 weeks. Weight fell 2.9% and waist size 5.6 cm, and 38 (95%) completed the study. Weight and waist rebounded significantly once treatment ended.
Is GLP-1 microdosing a reasonable idea for people with HIV?
GLP-1 microdosing for people with HIV is an untested idea built on tested ingredients. The trials show that semaglutide at 1 mg weekly works on the specific problems that modern HIV care produces: visceral fat, fatty liver and steady weight gain. They also show that the benefit fades after stopping. What they do not show is whether a dose below 1 mg keeps any of that benefit, or whether it lowers side effects enough to matter.
A few practical points follow from the evidence that exists:
- Involve the HIV clinician from the start. The studies above all enrolled people with a suppressed viral load on stable antiretroviral therapy.
- Do not expect a regimen switch alone to fix weight gain. The Do IT trial found no clinically meaningful benefit from switching to doravirine.
- Plan for maintenance before starting. Both SLIM LIVER and the lipohypertrophy trial saw weight and fat return after stopping.
- Protect muscle with resistance training and adequate protein, since psoas volume fell 9.3% in SLIM LIVER.
- Ask about drug interactions. These trials did not report interaction problems, but they were small, and our article on GLP-1 medication interactions and oral absorption explains why timing of oral medicines can matter.
For people with HIV, GLP-1 medicines have real trial data behind them for belly fat, liver fat and weight. Microdosing does not. Any lower-dose plan is an extrapolation and belongs in a conversation with the HIV care team.
Frequently asked questions
Can people with HIV take GLP-1 medicines like semaglutide?
Yes, GLP-1 medicines have been studied in people with HIV whose virus is controlled on antiretroviral therapy. A placebo-controlled trial of semaglutide in 108 people with HIV-associated belly fat, and the single-arm SLIM LIVER study, both reported meaningful fat and weight loss. Starting one should be coordinated with the HIV care team.
Why do people gain weight on modern HIV medicines?
Weight gain after starting HIV treatment comes from several sources, including a return to health and the regimen itself. A pooled analysis of 8 randomized trials linked integrase inhibitors such as dolutegravir and bictegravir, and tenofovir alafenamide, with more weight gain than older drugs. Female sex, Black race and a low CD4 count at the start also predicted more gain.
Will switching HIV medicines reverse integrase inhibitor weight gain?
The best evidence says probably not. In the Do IT randomized trial, 147 people with HIV and obesity on an integrase inhibitor with TAF/FTC were switched to doravirine or kept on their regimen. After 48 weeks there were no clinically meaningful differences in weight or metabolic health between the groups.
Does semaglutide reduce HIV-associated belly fat?
In the Eckard trial published in The Lancet Diabetes & Endocrinology in 2024, semaglutide cut visceral belly fat by 30.6% over 32 weeks compared with placebo. Total body fat fell 18.9% and abdominal fat under the skin fell 11.2%. The trial used a 1.0 mg weekly maintenance dose.
Has anyone studied GLP-1 microdosing in people with HIV?
No trial has tested sub-label microdoses in people with HIV. The lowest dose studied in these trials was semaglutide 1 mg weekly, which the SLIM LIVER investigators described as low-dose. Any lower regimen is outside the evidence.
What happens when people with HIV stop semaglutide?
Weight comes back. In SLIM LIVER, people lost a mean 7.8 kg over 24 weeks on semaglutide 1 mg and regained 2.9 kg in the 24 weeks after stopping, with waist size and fasting glucose rising too. The lipohypertrophy trial also found partial rebound in weight, visceral fat and insulin resistance after stopping.
Does semaglutide cause muscle loss in people with HIV?
Some muscle is lost along with fat. In SLIM LIVER, psoas muscle volume fell 9.3% over 24 weeks on semaglutide. Physical function held up, though, and the share of people with slow walking speed fell from 63% to 46%, which suggests function was preserved.
Is semaglutide safe alongside antiretroviral therapy?
The placebo-controlled lipohypertrophy trial found no statistically significant excess of related adverse events with semaglutide, but it was small. It recorded one semaglutide-related grade 4 lipase elevation and two possibly related cases of gallstones. The authors called for larger trials to look for serious adverse events in people with HIV.
Clinical references
- Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciz999
- Sokhela S, Venter WDF, Bosch B, et al. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infectious Diseases. 2024. doi:10.1093/ofid/ofae007
- Koethe JR, Lake JE, Kantor A, et al. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag196
- Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. The Lancet Diabetes & Endocrinology. 2024. doi:10.1016/S2213-8587(24)00150-5
- Adekunle RO, Wu Q, Sattar A, et al. Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial. Open Forum Infectious Diseases. 2026. doi:10.1093/ofid/ofag631
- Erlandson KM, Kitch DW, Kantor A, et al. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf652
- Ditzenberger GL, Lake JE, Kitch DW, et al. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae384
- Lake JE, Kitch DW, Kantor A, et al. Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study. HIV Medicine. 2026. doi:10.1111/hiv.70292
- Nguyen Q, Wooten D, Lee D, et al. Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae151
- Behuhuma N, Gasa G, Derache A, et al. Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag337
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for the clinicians who manage your HIV care or prescribe your medicines. Sub-label "microdose" regimens of GLP-1 medicines have not been tested in clinical trials, including in people with HIV. Never change or stop antiretroviral therapy without your HIV clinician. Charts show values reported in the cited studies.